ArticleFrontiers in oncology2026
Efficacy and safety of neoadjuvant immune checkpoint inhibitors combined with chemotherapy in locally advanced hypopharyngeal squamous cell carcinoma: a retrospective analysis.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To evaluate the efficacy and safety of neoadjuvant PD-1 inhibitor combined with chemotherapy (nab-paclitaxel + cisplatin) in patients with locally advanced hypopharyngeal squamous cell carcinoma. Methods: A retrospective analysis was conducted on 75 patients with locally advanced (stage III-IVA) hypopharyngeal cancer diagnosed at the First Affiliated Hospital of Xiamen University between January 2021 and May 2023. All patients received at least 2 cycles of neoadjuvant immunochemotherapy followed by radical surgery and adjuvant radiotherapy. Objective response rate (ORR), major pathological response (MPR), pathological complete response (pCR), larynx-preserving surgery rate, progression-free survival (PFS), and safety were evaluated. Results: Among 75 patients, the ORR was 77.3% (58/75), MPR rate was 78.7% (59/75), standard pCR rate (primary + lymph nodes) was 17.3% (13/75), primary tumor pCR rate was 26.7% (20/75), and larynx-preserving surgery rate was 86.7% (65/75). With a median follow-up of 26 months, the 12-month and 24-month overall survival rates were 93.3% and 76.0%, respectively, and the PFS rates were 92.0% and 76.0%, respectively. The MPR group demonstrated significantly superior PFS compared to the non-MPR group (HR = 0.052, 95% CI: 0.019-0.140, Conclusion: Neoadjuvant PD-1 inhibitor combined with chemotherapy induces significant radiological and pathological responses in patients with locally advanced hypopharyngeal cancer, effectively improving larynx-preserving surgery rate and progression-free survival with a favorable safety profile. Pathological assessment (particularly MPR) may provide complementary prognostic information to radiological assessment.This regimen demonstrates promising short-term efficacy and larynx preservation benefits, warranting further prospective validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.